![Clarissa Sowemimo-Coker](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Clarissa Sowemimo-Coker
Amministratore Delegato presso OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC
Patrimonio netto: 4 300 $ in data 31/05/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Indraneil Mahapatra | M | 44 |
Oxford Cannabinoid Technologies Ltd.
![]() Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | 7 anni |
Charanjit Dhillon | F | 66 |
Oxford Cannabinoid Technologies Ltd.
![]() Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | - |
Julie Pomeroy | F | 69 | - | |
Timothy Corn | M | 73 | 1 anni | |
Karen Lowe | F | 55 |
Oxford Cannabinoid Technologies Ltd.
![]() Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | - |
John Lucas | M | 58 |
Oxford Cannabinoid Technologies Ltd.
![]() Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | 3 anni |
Paul Smalley | M | - | 2 anni | |
Robin Bennett | M | - | 2 anni | |
Richard Hathaway | M | 57 |
Oxford Cannabinoid Technologies Ltd.
![]() Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | - |
Bishrut Mukherjee | M | 37 |
Oxford Cannabinoid Technologies Ltd.
![]() Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | - |
Valentino Parravicini | M | 55 | 4 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Hee-Dong Kim | M | - |
Oxford Cannabinoid Technologies Ltd.
![]() Oxford Cannabinoid Technologies Ltd. Pharmaceuticals: OtherHealth Technology Oxford Cannabinoid Technologies Ltd. engages in researching, developing and licensing cannabinoid-based compounds and therapies. Its therapies are used in medical applications, such as inflammatory diseases (arthritis, and auto-immune inflammatory and inflammatory eye diseases), oncology, neurological disorders (addiction, Alzheimer’s, depression, epilepsy, and Parkinson’s disease) and pain management. The company was founded in 2017 and is headquartered in Oxford, the United Kingdom. | 4 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Regno Unito | 12 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Clarissa Sowemimo-Coker
- Contatti personali